News & Updates

Show Multimedia Only

Timing of chemo during pregnancy may affect congenital malformation risk

10 Aug 2021 by

Exposure to chemotherapy in the first 12 weeks of pregnancy may be associated with an increased risk of major congenital malformations in offspring, a recent study showed.

Timing of chemo during pregnancy may affect congenital malformation risk

10 Aug 2021

Cetuximab plus afatinib combo of no benefit in advanced EGFR-mutant NSCLC

07 Aug 2021

Use of cetuximab in combination with afatinib for the first-line treatment of patients with advanced nonsmall cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) mutation does not appear to improve outcomes as compared with afatinib alone, according to the results of a phase II trial.

Cetuximab plus afatinib combo of no benefit in advanced EGFR-mutant NSCLC

07 Aug 2021

Colorectal cancer screening and early diagnosis: Are expansion and partnership feasible?

07 Aug 2021 by

MOH’s Disease Control Division (DCD) collaborated with the Digestive Health Malaysia (DHM) and Clinical Research Centre Hospital Sultanah Bahiyah (CRCHSB), Alor Star, Kedah, to organize a virtual Colorectal Cancer Screening Symposium recently.

Colorectal cancer screening and early diagnosis: Are expansion and partnership feasible?

07 Aug 2021

Has COVID-19 changed the pathological outcomes in prostate cancer?

05 Aug 2021 by

The likelihood of pT3* or higher tumours and node-positive disease found at the time of radical prostatectomy (RP) for prostate cancer (PCa) was greater during the COVID-19 pandemic than it was before, an expert reported at EAU21.

Has COVID-19 changed the pathological outcomes in prostate cancer?

05 Aug 2021

Adjuvant olaparib extends DFS in high-risk BRCA1/2-mutated HER2-negative early breast cancer

04 Aug 2021 by

Adjuvant olaparib for 1 year following local treatment and adjuvant/neoadjuvant chemotherapy improved disease-free survival (DFS) in patients with HER2-negative early breast cancer (EBC) with BRCA1 or BRCA2 pathogenic/likely pathogenic variants and high recurrence risk, according to interim results of the multinational, phase III OlympiA study.

Adjuvant olaparib extends DFS in high-risk BRCA1/2-mutated HER2-negative early breast cancer

04 Aug 2021

Treatment-related amenorrhea common in young breast cancer patients

04 Aug 2021

Young women with breast cancer who are receiving treatment with modern chemotherapy regimens are likely to develop short episodes of treatment-related amenorrhea, but the vast majority of them will maintain or regain menstrual function, a study has found.

Treatment-related amenorrhea common in young breast cancer patients

04 Aug 2021

Multitarget FIT better than standard test for colorectal cancer screening

02 Aug 2021

A multitarget faecal immunochemical test (mtFIT) is more accurate than conventional FIT in detecting advanced neoplasia due to an increased detection of advanced adenomas, according to a study.

Multitarget FIT better than standard test for colorectal cancer screening

02 Aug 2021

Taiwan study: No link between drinking and pancreatic cancer

27 Jul 2021

Alcohol consumption does not seem to substantially impact population occurrence rates of pancreatic cancer, a recent Taiwan study has found. This null effect seems to hold even among people who are genetically susceptible to the carcinogenicity of alcohol.

Taiwan study: No link between drinking and pancreatic cancer

27 Jul 2021

Targeted radioligand therapy ups survival in previously-treated mCRPC

27 Jul 2021 by

Adding the lutetium-labelled PSMA*-617 (177Lu PSMA-617) targeted radioligand therapy to standard of care (SOC) led to significant extension of radiographic progression-free survival (rPFS) and overall survival (OS) compared with SOC alone in patients with metastatic castration-resistant prostate cancer (mCRPC) who had progressed after treatment with chemotherapy and androgen inhibitors, according to the VISION trial presented at ASCO 2021.

Targeted radioligand therapy ups survival in previously-treated mCRPC

27 Jul 2021

No excess risk of gastrointestinal malignancies with ranitidine vs other reflux drugs

27 Jul 2021

Use of the histamine-2 receptor antagonist ranitidine does not appear to increase the likelihood of developing gastrointestinal malignancies as compared with omeprazole or famotidine, as shown in a study.

No excess risk of gastrointestinal malignancies with ranitidine vs other reflux drugs

27 Jul 2021

News & Updates

Filter by Specialty:

Specialty:

Timing of chemo during pregnancy may affect congenital malformation risk

Timing of chemo during pregnancy may affect congenital malformation risk

Cetuximab plus afatinib combo of no benefit in advanced EGFR-mutant NSCLC

Cetuximab plus afatinib combo of no benefit in advanced EGFR-mutant NSCLC

Colorectal cancer screening and early diagnosis: Are expansion and partnership feasible?

Colorectal cancer screening and early diagnosis: Are expansion and partnership feasible?

Has COVID-19 changed the pathological outcomes in prostate cancer?

Has COVID-19 changed the pathological outcomes in prostate cancer?

Adjuvant olaparib extends DFS in high-risk BRCA1/2-mutated HER2-negative early breast cancer

Adjuvant olaparib extends DFS in high-risk BRCA1/2-mutated HER2-negative early breast cancer

Treatment-related amenorrhea common in young breast cancer patients

Treatment-related amenorrhea common in young breast cancer patients

Multitarget FIT better than standard test for colorectal cancer screening

Multitarget FIT better than standard test for colorectal cancer screening

Taiwan study: No link between drinking and pancreatic cancer

Taiwan study: No link between drinking and pancreatic cancer

Targeted radioligand therapy ups survival in previously-treated mCRPC

Targeted radioligand therapy ups survival in previously-treated mCRPC

No excess risk of gastrointestinal malignancies with ranitidine vs other reflux drugs

No excess risk of gastrointestinal malignancies with ranitidine vs other reflux drugs